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EXPERIENCE WITH 
REPAIR OF CONGENITAL 
HEART DEFECTS 
USING ADJUNCTIVE 
ENDOVASCULAR DEVICES 
The use of endovascular devices as an adjunct to repair of congenital heart 
anomalies represents a novel but unproven therapeutic approach. Intraoper- 
ative implantation of pulmonary arterial stents (5 to 15 mm diameter) was 
done in 11 patients with pulmonary atresia with ventricular septal defect (n = 
4), classic tetralogy of Fallot (n = 2), truncus arteriosus (n = 1), hypoplastic 
left heart syndrome (stage II [n = 1] and stage II I  In = 1] Norwood 
procedure), and miscellaneous pulmonary arterial stenoses (n = 3), as well as 
in patients with congenital (n = 1) and postoperative (n = 3) pulmonary 
venous osbstruction and in 1 patient with combined pulmonary arteria~ and 
venous obstruction. The stents were effective at achieving immediate patency in 
all patients. There were two early deaths, one related to acute thrombosis of a 
small-diameter left pulmonary artery stent. Reintervention because of stent- 
related pulmonary arterial stenosis was frequently necessary. In five of seven 
patients who survived more than I month after implantation of stent size 8 mm 
or smaller severe stent-related pulmonary arterial obstruction developed. In 
four of the five patients with pulmonary vein stent implantation intractable 
obstruction developed, resulting in death in all three patients who had bilateral 
pulmonary vein stent implantation. Intraoperative occlusion of apical muscu- 
lar ventricular septal defect with use of a clamshell device inserted from the 
right atrial approach was accomplished in four patients. One patient who 
underwent associated aortic arch reconstruction died as a result of left 
ventricular hypoplasia. The results in the remaining three patients were 
favorable on the basis of absence of significant late residual intraventricular 
shunting, left ventricular dysfunction, or arrhythmia. We conclude that 
recurrent intraluminal obstruction as a result of neointimal hyperplasia 
appears to be an eventual certainty in currently designed small-diameter 
endovascular stents. For this reason, we would recommend standard surgical 
techniques for repair of obstructive lesions of the pulmonary arterial conflu- 
ence to maximize growth potential. Device occlusion of muscular ventricular 
septal defects is feasible but probably only indicated for complex cases of 
ventricular septal deficiency that otherwise necessitate  l ft ventriculotomy. 
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accrued experience with percutaneous transcatheter 
insertion of endovascular stents for balloon dilation- 
resistant pulmonary arterial stenosis has been favor- 
able, 13 there is limited information concerning the 
intermediate-term effects of these devices on the 
pulmonary vasculature. 
Preoperative transcatheter closure of congenital 
muscular ventricular septal defects (VSDs) has been 
reported to facilitate subsequent surgical repair of 
associated lesions and, in some cases, to obviate the 
need for a left ventricular incision for patch closure 
of complex deficiency of the ventricular septum. 4 
Intraoperative insertion of clamshell devices has 
been successfully used to occlude muscular VSDs 
and may be accomplished with greater technical 
simplicity than can be achieved with the use of 
interventional catheterization techniques. 5 
Review of our experience with adjunctive endo- 
vascular devices with intermediate-term follow-up 
revealed several important problems that seriously 
detract from the apparent advantage of technical 
simplicity in comparison with conventional surgical 
techniques. The major problem identified with the 
endovascular stents is the virtually invariable devel- 
opment of recurrent intraluminal obstruction, which 
seriously complicated the treatment of patients who 
received small-diameter stents for treatment of pul- 
monary arterial and venous obstructive lesions. 
Patients and methods 
The complete xperience with intraoperative implanta- 
tion of endovascular devices at The Hospital for Sick 
Children, Toronto, includes 20 patients who underwent 
the following procedures during the period October 1991 
to August 1994: stenting of branch pulmonary arteries 
(n = 11), stenting of pulmonary veins (n = 4), combined 
pulmonary arterial and venous implantation (n = 1), and 
device closure of muscular VSD (n = 4). 
Pulmonary artery stents. The morphologic diagnoses 
of the 11 patients who underwent pulmonary arterial stent 
implantation (Palmaz stainless steel intraluminal stent, 
Johnson and Johnson Systems, Somerville, N.J.) included 
pulmonary atresia with VSD (n = 4), classic tetralogy of 
Fallot (n = 2), truncus arteriosus (n = 1), hypoplastic left 
heart syndrome (stage II [n = 1] and stage III [n = 1] 
Norwood procedure), and (n = 1 each) aortopulmonary 
window, pulmonary atresia with intact ventricular septum, 
and tricuspid atresia with absent pulmonary valve syn- 
drome. One patient with tetralogy of Fallot underwent 
simultaneous stent implantation i to the right pulmonary 
artery and the left pulmonary veins. 
The patients ages ranged from 4 days to 16 years. All 
patients have been evaluated with postoperative cardiac 
catheterization a d angiography, and the mean follow-up 
period is 24.7 months. Pulmonary arterial stents were 
implanted unilaterally in seven patients and bilaterally in 
five. intraoperative stent implantation was done at the 
time of primary repair in five patients and at a reoperation 
in eight patients. 
Pulmonary venous stent implantation. Pulmonary ve- 
nous stent implantation was done in five patients. In three 
patients pulmonary vein stenosis developed subsequent to
repair of supracardiac (n = 1) or coronary sinus (n = 2) 
total anomalous pulmonary venous connection; the re- 
maining patients had presumably congenital pulmonary 
vein stenosis in association with pulmonary atresia with 
intact ventricular septum (n = 1) and tetralogy of Fallot 
(n = 1). Bilateral pulmonary venous stent implantation 
was done in four patients and unilateral pulmonary ve- 
nous stenting, to both the upper and lower lobe branches, 
in two patients. The stent diameter anged from 6 to 10 
mm at the time of implantation. 
Technique of endovascular device insertion. Intraoper- 
ative stent implantation was done under direct vision over 
a balloon dilation catheter to achieve an effective stent 
diameter ranging from 5 to 15 mm. In all cases, the stents 
were inserted across the ostium of one or both pulmonary 
arteries uch that a short segment of the expanded stent 
remained within the main pulmonary trunk. In the case of 
obstruction i volving the ostia of pulmonary veins, a short 
length of the stent protruded into the left atrium proper. 
Device occlusion of muscular VSD. Intraoperative de- 
vice occlusion of a muscular VSD was done in three 
neonates and one infant (weight range 3.0 to 8.1 kg). The 
position of the defect was apical in three patients and 
midmuscular in one. 
VSD closure was accomplished with a 17 mm USCI 
clamshell device (Bard Clamshell Septal Umbrella, USCI 
Division, C.R. Bard, Billerica, Mass.) in three patients; a
Rashkind ductal occlusion device was used in one patient. 
Operation was done for the express purpose of device 
closure of a muscular VSD in two patients; 1patient each 
underwent concomitant patch enlargement of branch 
pulmonary arteries and polytetrafluoroethylene patch an- 
gioplasty of a hypoplastic aortic arch. 
Technique used for device occlusion. The muscular 
VSD was identified by probing the left ventricular aspect 
of the septum with a right-angled evice passed through 
an associated atrial septal defect from the right atrial 
approach. The right-angled clamp was then used to grasp 
a large silk suture attached to the clamshell device deliv- 
ery sheath. The silk suture was then used to guide the 
delivery sheath across the VSD through the right ventric- 
ular orifice, facilitating sequential release and engagement 
of the left ventricular and right ventricular components of
the clamshell device. The device was directly inserted into 
the single patient with a midmuscular VSD without suture 
guidance. 
Results 
Pulmonary arterial stent implantation. There 
were three deaths in this group. One patient died 
with low cardiac output syndrome after bilateral 
pulmonary arterial stent implantation to correct 
pulmonary arterial confluence stenosis after repair 
of truncus arteriosus. One patient with tricuspid 
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atresia nd absent pulmonary valve syndrome with a 
left pulmonary artery stent died as a result of sepsis 
and inability to regulate pulmonary blood flow. The 
third patient died after bilateral pulmonary arterial 
stent implantation done at the time of repair of 
pulmonary atresia with VSD (described later). 
Reinterventions for stent-related pulmonary ar- 
terial stenosis. Ten eligible patients underwent 13 
postoperative cardiac catheterizations at a mean 
interval of 9.6 months after stent implantation. On 
the basis of results of the first cardiac catheteriza- 
tion, there was a mean reduction of 56% in the 
effective caliber of the stented pulmonary artery 
relative to intraoperative measurements. Dilation of 
the stented pulmonary tery segments was done in 
6 of 10 eligible patients and in 6 of 13 eligible 
stented branch pulmonary arteries; 3 patients re- 
quired 2 dilation procedures and 1 patient required 
3. Variable improvement in the caliber of stented 
pulmonary artery segments on the basis of angio- 
graphic assessment was observed after stent dilation. 
Five of seven patients who survived more than 1 
month after implantation of a stent size 8 mm or 
smaller had the development of severe stent-related 
pulmonary arterial obstruction. 
Reoperation to correct stent-related stenosis of 
the pulmonary arterial confluence was successfully 
done in two patients by pericardial patch arterio- 
plasty at 8 and 12 months after initial stent implan- 
tation. 
Neonatal pulmonary atresia with VSD. Three 
patients underwent s ent implantation in an attempt 
to overcome ductal-related constriction i  the left 
pulmonary artery at the time of neonatal repair. In 
one patient, this necessitated implantation of two 
overlapping stents in the left pulmonary artery to 
effectively straddle the area of ductal insertion. In 
this patient hrombosis developed within the stents 
resulting in a 1 mm residual patent lumen, which led 
to death 2 weeks after operation. In all three 
patients, gmm stent implantation i to the ostium of 
the left pulmonary artery resulted in distortion of 
the ostium of the contralateral right pulmonary 
artery, which necessitated right pulmonary artery 
stent implantation concomitantly (n = 2) or at a 
reoperati0n (n = 1). Reoperation for stent-related 
pulmonary arterial steflosis (bilateral in 1; unilateral 
in 1) was required at 4 months and 12 months, 
respectively, after initial stent implantation (Fig. 1). 
In both cases, the stents were opened lengthwise 
and the branch pulmonary arteries uccessfully aug- 
mented with pericardial patches. 
Pulmonary venous stent implantation. The three 
patients with bilateral stent implantation died at 4, 
15, and 24 months after operative stent implantation 
as a result of progressive, bilateral, intraluminal 
obstruction. The obstruction occurred within the 
stented segment in all patients and extended into 
nonstented parenchymal segments ofthe pulmonary 
veins bilaterally in one patient (Fig. 2). Among these 
three nonsurviving patients, one underwent an at- 
tempted stent dilation and another an unsuccessful 
revision with excision of neointimal hyperplasia. 
Among the two surviving patients who had unilat- 
eral pulmonary venous tent implantation, one un- 
derwent balloon dilation with modest caliber im- 
provement at 17 months after implantation; the 
other patient is doing well clinically with no evi- 
dence of obstruction in the single pulmonary vein 
branch evaluable by two-dimensional echocardiog- 
raphy. 
Device closure of muscular VSD. The patient 
with a midmuscular VSD died with low cardiac 
output syndrome. Postmortem examination demon- 
strated satisfactory occlusive position of the device; 
the presence of moderately severe left ventricular 
and mitral annular hypoplasia was the presumed 
cause of death (Fig. 3). One patient in whom the 
Rashkind uctal occlusion device was used required 
reoperation to close a peridevice residual defect in 
association with a residual eak of a perimembra- 
nous defect originally treated by patch closure. This 
patient still had a small residual VSD at the time of 
most recent follow-up. In one patient unexplained 
complete heart block developed subsequent to de- 
vice closure of an apical muscular VSD. 
In the two surviving patients treated with a clam- 
shell occlusion device followed up 11 to 52 months 
after implantation, there is no evidence of residual 
intraventricular shunting or ventricular dysfunction 
as assessed by postoperative echocardiography and 
left ventricular angiography. 
Discussion 
Transcatheter deployment ofballoon-expandable 
endovascular stents has been successfully applied in 
the treatment ofcongenital nd acquired pulmonary 
arterial stenosis. 1'2 This technique has also been 
successfully used to increase the caliber of aorto- 
pulmonary collaterals, 6 obstructed right ventricular 
outflow tract conduits, 7 and systemic and pulmonary 
venous pathways after the atrial switch operation s 
and as a means to maintain patency of the ductus 
arteriosus 6 and the native right ventricular outflow 
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Fig. 1. A, Preoperative angiogram in neonate with pulmonary atresia nd VSD showing ductal insertion 
onto origin of left pulmonary artery producing potential for pulmonary arterial confluence stenosis. B, 
Severe, bilateral proximal pulmonary artery stenosis that occurred four months after insertion of 
endovascular stents across origin of both branch pulmonary arteries and inflation of stents to 5 mm 
diameter. 
tract in pulmonary atresia after radiofrequency per- 
foration.9, 10 Mendelsohn and colleagues 5 first re- 
ported the use of intraoperative endovascular stents, 
citing the potential advantages of this approach in 
patients undergoing the Fontan procedure in whom 
percutaneous vascular access to the pulmonary ar- 
teries may be difficult preoperatively. 
Review of our experience with intraoperative 
balloon-expandable stent implantation revealed a 
high prevalence of recurrent intraluminal obstruc- 
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Fig. 2. Section taken through right upper lobe pulmonary vein immediately upstream of site of 
endovascular stent implantation. Severe intimal hyperplasia s present, attributable tosmooth muscle cell 
proliferation and extensive xtracellular matrix material, consisting of predominantly glycosaminoglycans, 
collagen, and disorganized lastic fiber production (Movat stain; original magnification ×20). 
Fig. 3. Autopsy specimen illustrating satisfactory left ventricular position of 17 mm USCI clamshell 
dev!ce. Marked mitral annular and left ventricular hypoplasia were present. 
tion within the stent. This finding was especially 
conspicuous and hemodynamically important in 
small-diameter stents placed in the neonatal pul- 
monary arterial confluence, but was also observed 
in larger stents up to 16 mm in initial implant 
diameter. 
This result is consistent with our institutional 
experience with percutaneous transcatheter inser- 
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tion of balloon-expandable endovascular stents. 
Follow-up cardiac atheterization and selective pul- 
monary artery angiography done in 42 patients who 
underwent this procedure identified endoluminal 
tissue ingrowth occurring to varying degrees in all 
stents; subsequent further dilation was required in 
11 patients (26%) during a median follow-up of 15 
months. 3 Usually a modest but significant improve- 
ment in the caliber of the vessel at the site of the 
stent was accomplished by dilation both in the 
present surgical series and in the group undergoing 
transcatheter pulmonary arterial stent implantation. 
In contrast, O'Laughlin and colleagues 2 reported 
angiographic evidence of restenosis n only 1 of 25 
patients undergoing transcatheter pulmonary arte-
rial stent implantation, although in the majority of 
stents there was a 1 to 2 mm thick layer of intimal 
proliferation evident. In that series, redilation of 17 
stents in 14 patients increased the narrowest stent 
diameter from 9.0 mm to 11.8 mm (p < 0.01), 
implying a consistent but finite susceptibility to 
increasing the effective diameter of chronically im- 
planted stents. The higher rate of stent-related 
obstruction i  our institutional experience with in- 
terventional nd surgical stent implantation relative 
to that of O'Laughlin and colleagues a is likely 
related to the greater size and age range and the 
predominant use of larger "iliac" stents in their 
series. 
The development of stent-related obstruction was 
especially pernicious in the group of patients who 
underwent stent implantation to correct pulmonary 
venous obstruction. All five patients who underwent 
operative stent implantation to correct pulmonary 
vein stenosis, as well as two additional patients in 
whom a pulmonary venous stent implantation was 
accomplished at cardiac catheterization, had the 
development of progressive and intractable obstruc- 
tion within months after stent implantation. This 
process was fatal in the three patients with bilateral 
pulmonary venous tent implantation. This result is 
consistent with that in the report from the Univer- 
sity of Michigan Medical Center involving three 
patients who had stent implantation to correct pul- 
monary vein stenosis,  
Restenosis occurring within endovascular stents 
appears to be a consequence of luminal encroach- 
ment by neointimal hyperplasia. 11 The initial tissue 
response after stent implantation is that of thrombus 
deposition in proximity to the stents with retention 
of intervening endothelial cells. 12 Within a few days 
to weeks, smooth muscle cell proliferation, eovas- 
cularization, and extracellular matrix deposition 
develop eccentrically from the site of the stent 
latticework. The precise stimuli that cause cellular 
proliferation and synthesis of intracellular matrix in 
the presence of metallic stents, as well as the 
potential for remodeling and regression, remain 
unknown.13, 14The tendency for the development of 
late restenosis is well recognized after coronary 
arterial stent implantation, which occurs with a time 
course and frequency similar to that after balloon 
angioplasty.15, 6 Both in the coronary artery experi- 
ence 17 and in our own experience with percutaneous 
transcatheter pulmonary arterial stent implanta- 
tion, 3 stent oversizing has been identified as a risk 
factor for restenosis and apparently eads to bstruc- 
tive lesions at the junction between the stent and the 
native vessel in cases in which the stent size is 
significantly larger than the adjacent vessel. 
Additional considerations militate against the use 
of small-diameter ndovascular stents in the man- 
agement of pulmonary arterial confluence stenosis 
in neonates and infants. In our experience, stent 
implantation across the origin of the left pulmonary 
artery to treat ductus-related stenosis invariably 
compromised the origin of the contralateral right 
pulmonary artery. Moreover, implantation of endo- 
vascular stents into growing pulmonary arteries may 
have the effect of fixing the caliber of the vessel and 
impairing the growth potential. Our experience sug- 
gests that further dilation of chronically implanted 
endovascular stents is usually possible, but limited in 
extent and unlikely to achieve maximal dilation to 
the nominal balloon-expandable st nt diameter. 
On the basis of these considerations, we would 
consider conventional patch angioplasty echniques 
preferable to the use of small-diameter endovas- 
cular stents in the treatment of pulmonary arterial 
and pulmonary venous obstruction, recognizing 
the poor prognosis associated with the diffuse 
forms of pulmonary venous obstruction with any 
treatment modality. On the other hand, percutane- 
ous transcatheter deployment of dovascular stents 
may represent the safest and most effective method 
to achieve satisfactory vessel caliber in obstructed 
pulmonary arteries of any size in the immediate 
postoperative p riod, in which circumstances surgi- 
cal revision may carry an unacceptably high risk. 
Improvements in coronary artery stent design, such 
as the development of drug-eluting and biodegrad- 
able polymer stents, may ultimately be beneficially 
applicable to obstructive congenital lesions. 15 
Our small experience with percutaneous trans- 
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catheter and intraoperative device occlusion of mus- 
cular VSDs indicates that these approaches are 
effective in the short-term in providing closure of 
the defect, This finding supports those of Bridges 
and associates 4 and Fischberger, Bridges, and 
Keane, 18 who additionally concluded that, in the 
case of multiple VSDs, transcatheter closure was 
preferable to intraoperative closure inasmuch as it 
allows angiographic definition and immediate man- 
agement of residual defects after initial device im- 
plantation. The device-related perforation of the 
left ventricle in one of our patients, however, raises 
concerns about the long-term durability and safety 
of ventricular septal devices. With this in mind, and 
on the basis of our favorable experience with con- 
ventional patch closure of apical muscular VSDs by 
use of a limited apical right ventricular incision, we 
would currently reserve consideration of device clo- 
sure of VSDs for complex cases of severe ventricular 
septal deficiency that otherwise necessitate a left 
ventriculotomy. 
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Discuss ion  • 
Dr. Pedro J. del Nido (Boston, Mass.). The experience 
at Boston Children's Hospital with device closure of 
VSDs, which has been previously reported, includes a 
total of 10 patients. Four patients had multiple VSDs, or 
"Swiss cheese septum," and eight had additional complex 
defects. The overall results included three early deaths, 
two of which were related to residual shunts that were 
significant and compromised cardiac output. The third 
was related, at least in part, to the manipulation required 
to insert his occluder device in the apex. This was a result 
of difficult visibility and retraction of the ventricle. 
One additional problem that may come up, and we 
would like to ask the authors if they have seen this, is the 
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inability to determine where the distal end of the balloon 
is in relation to the branch pulmonary arteries. One of the 
potential problems is inserting the guide wire into a small 
branch, causing a tear or an aneurysmal dilatation of the 
branch pulmonary arteries when the balloon is dilated. 
Although the authors stated that all the balloons were 
inserted under direct vision, the distal end of the balloon 
cannot be visualized by this modality. 
The problems that we have found with intraoperative 
interventions, in summary, are, first, with VSD occlusions, 
the inability to detect residual defects or residual obstruc- 
tion before discontinuation f bypass; second, the inability 
to determine the distal position of the dilating balloon or 
of the stent, which may lead to pulmonary artery damage 
distally; and, finally, the difficulty in exposure that occurs 
when one is attempting to close the VSD. This is partic- 
ularly true with apical VSDs. 
One additional question that I would like to ask is 
whether the authors noticed in their experience any 
differences between the apical and the midmuscular VSDs 
with respect to the ease of insertion of the device and with 
the degree of distortion required for exposure. Could, 
perhaps, the small but significant prevalence of heart 
block reported be related to the manipulation of the 
ventricle? 
Dr. Coles. We have no experience in using these devices 
in cases of either percutaneously or intraoperatively, and 
agree that it may be advantageous to do such procedures 
in the catheterization laboratory so that one can identify 
any residual leaks, because it has been shown that many of 
these patients with complex left ventricular VSD, require 
insertion of multiple devices to successfully achieve occlu- 
sion. 
I also concur that positioning of stents in the distal 
pulmonary artery tree intraoperatively may be difficult, 
simply because, as indicated, one cannot determine se- 
curely where the distal extent of the stent is. In our series 
the stents were placed across the origin of the broncho- 
pulmonary artery, so it was less of a problem. However, in 
one baby, weary of trying to basically obviate a ductal 
constriction-related stenosis, we finally used two stents, 
and I think our inability to adequately position the distal 
end of the more distal stent contributed to the acute 
thrombosis in that patient. 
In terms of exposure of the apical VSDs, we found that 
the technique was fairly straightforward, although I agree 
that the unexplained complete heart block in one patient 
might be related to manipulation. 
With respect o your question about apical defects, we 
have experience closing several of these defects with use 
of an apical right ventricular incision rather than an apical 
left ventricular incision, and we think that is the preferred 
way to do it, particularly in view of our experience in the 
one patient in whom the device migrated. We also heard 
recently from Dr. Lock that there is a fairly high preva- 
lence of strut fracture, not only in the atrial position but 
also in the ventricular position, so we think it is safer and 
more secure to close these lesions by a convention patch 
closure, working through either the right atrium or the 
right ventricle. 
Dr. Richard A. Hopkins (Washington, D.C.). I have two 
questions. First, I am going to pin you down as to your 
feeling about what size stent is too small: what is your 
cutoff for using stents in the pulmonary arteries now? 
Second, in the patients who underwent reoperation after 
having stents placed, did you remove the stent or did you 
cut across it, and how difficult was that operation? 
Dr. Coles. There were seven patients, I believe, who had 
a stent size of 8 mm or less, at least that was the diameter 
that they were inflated to at the time of the initial implant, 
and five of those patients had severe recurrent obstruction 
necessitating intervention either in the form of operation 
or one or more dilations. Having said that, I do not think 
that is necessarily a discrete threshold size, because there 
were patients with larger stents, including a patient with a 
15 or 16 mm stent, who required further dilations. I do not 
think any stent size is immune from the problem of 
neointimal hyperplasia. 
There were two patients in this series in whom we had 
to cut across the stent, plus some additional patients who 
underwent percutaneous transcatheter insertion of endo- 
vascular stents, who subsequently required a pulmonary 
arterioplasty. This can be done, but it is not easy, because 
the marginal protruding stents must be removed to secure 
the patch in position. When that is done and when they 
are peeled back, they tend to be well heeled into the 
pulmonary artery, and thus the pulmonary artery can 
become frayed, making the subsequent suturing difficult, 
although we were able to do it. I think this is another 
disadvantage of the stents. 
